Advances in Targeted Therapies for SCLC Care

Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer (SCLC) and how they are changing the standard of care.

Lopez-Chavez highlights the FDA approval of tarlatamab-dlle (Imdelltra), a bispecific T-cell engager (BiTE), for the treatment of SCLC that has progressed on or after platinum-based chemotherapy, updates from the phase 3 IMforte study (NCT05091567) of lurbinectedin (Zepzelca) plus the PD-L1 inhibitor atezolizumab (Tecentriq) in extensive-stage SCLC, and more.

Transcription:

0:09 | There were 4 major advancements or major news in the world of small cell lung cancer [this year], and the first one came in May of this year with the approval of the first bispecific T-cell engager targeting DLL3. That was the approval of tarlatamab in May of this year, 2024.

0:32 | Then in June at [The American Society of Clinical Oncology Annual Meeting (ASCO), there was] the presentation of the results of the ADRIATIC trial [NCT03703297] in small cell lung cancer. Then in August, also, something very interesting [happened] in targeted therapies, [which] is that the FDA granted breakthrough therapy designation to the first B7-H3 targeted antibody-drug conjugate. And then finally just last week, the IMforte trial testing lurbinectedin in the maintenance setting after induction chemoimmunotherapy read out positive. That is an [important] phase 3 trial.

1:18 | So, a lot of excitement in the world of small cell lung cancer, and obviously, [this is] shaping the landscape of therapeutics already, right? Because that tarlatamab was used, approved. That is changing how we treat second-line small cell lung cancer, and then with the readout of the IMforte trial, that is changing how we treat small cell lung cancer in the limited-stage setting.